CA2826765C - Methods and compositions for improving cognitive function - Google Patents

Methods and compositions for improving cognitive function Download PDF

Info

Publication number
CA2826765C
CA2826765C CA2826765A CA2826765A CA2826765C CA 2826765 C CA2826765 C CA 2826765C CA 2826765 A CA2826765 A CA 2826765A CA 2826765 A CA2826765 A CA 2826765A CA 2826765 C CA2826765 C CA 2826765C
Authority
CA
Canada
Prior art keywords
cognitive impairment
oxo
hydrogen
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2826765A
Other languages
English (en)
French (fr)
Other versions
CA2826765A1 (en
Inventor
Michela Gallagher
Rebecca Haberman
Ming Teng Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2826765A1 publication Critical patent/CA2826765A1/en
Application granted granted Critical
Publication of CA2826765C publication Critical patent/CA2826765C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA2826765A 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function Active CA2826765C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441251P 2011-02-09 2011-02-09
US61/441,251 2011-02-09
PCT/US2012/024556 WO2012109491A1 (en) 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function

Publications (2)

Publication Number Publication Date
CA2826765A1 CA2826765A1 (en) 2012-08-16
CA2826765C true CA2826765C (en) 2021-04-06

Family

ID=46638963

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2826765A Active CA2826765C (en) 2011-02-09 2012-02-09 Methods and compositions for improving cognitive function

Country Status (9)

Country Link
US (2) US20120214859A1 (enExample)
EP (2) EP2672822A4 (enExample)
JP (7) JP2014505108A (enExample)
CN (2) CN103476255A (enExample)
AU (6) AU2012214303A1 (enExample)
BR (1) BR112013020283A2 (enExample)
CA (1) CA2826765C (enExample)
RU (1) RU2665021C2 (enExample)
WO (1) WO2012109491A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
WO2014144546A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositons for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
EA034167B8 (ru) * 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN112569216B (zh) * 2019-09-30 2022-02-15 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
US20250213727A1 (en) 2022-03-25 2025-07-03 Regenxbio Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN115517682B (zh) * 2022-11-25 2023-01-31 四川大学华西医院 基于胃肠电信号的认知功能障碍预测系统及构建方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CN101027047A (zh) * 2002-12-03 2007-08-29 Ucb公司 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
ZA200508306B (en) * 2003-05-23 2007-03-28 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
PL1909764T3 (pl) * 2005-07-26 2015-03-31 Ucb Pharma Sa Kompozycje farmaceutyczne zawierające lewetyracetam i sposób ich wytwarzania
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2041084B1 (en) * 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
EP2346500B1 (en) * 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
CN101647789B (zh) * 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US10806717B2 (en) * 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function

Also Published As

Publication number Publication date
AU2016202670A1 (en) 2016-05-19
US20120214859A1 (en) 2012-08-23
CN103476255A (zh) 2013-12-25
RU2013141155A (ru) 2015-03-20
AU2021200325B2 (en) 2022-07-28
JP2025109773A (ja) 2025-07-25
EP2672822A4 (en) 2014-08-27
CA2826765A1 (en) 2012-08-16
EP2672822A1 (en) 2013-12-18
BR112013020283A2 (pt) 2016-07-19
AU2019268069A1 (en) 2019-12-12
AU2012214303A1 (en) 2013-09-12
RU2018129580A3 (enExample) 2022-03-25
JP2018100305A (ja) 2018-06-28
RU2665021C2 (ru) 2018-08-24
EP3400934A1 (en) 2018-11-14
CN109662961A (zh) 2019-04-23
JP2021175759A (ja) 2021-11-04
WO2012109491A1 (en) 2012-08-16
JP2014505108A (ja) 2014-02-27
JP2016172772A (ja) 2016-09-29
AU2018201303A1 (en) 2018-03-15
AU2022221492A1 (en) 2022-09-22
AU2021200325A1 (en) 2021-03-18
JP2020079318A (ja) 2020-05-28
RU2018129580A (ru) 2019-03-20
US20230033195A1 (en) 2023-02-02
JP2023126654A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
AU2021200325B2 (en) Methods and compositions for improving cognitive function
US20230277501A1 (en) Methods and compositions for improving cognitive function
CA2891122C (en) Methods and compositions for treating schizophrenia
CA2789014C (en) Methods and compositions for improving cognitive function
CA2904767C (en) Methods and compositions for improving cognitive function
US20160030391A1 (en) Methods and compositions for improving cognitive function
AU2018208662B2 (en) Methods and Compositions for Treating Schizophrenia
HK1261244A1 (en) Levetiracetam for improving cognitive function
RU2792010C2 (ru) Способы и композиции для улучшения когнитивных функций
HK40003608A (en) Methods and compositions for improving cognitive function
HK40021943A (en) Methods and compositions for treating schizophrenia
HK1192821A (en) Methods and compositions for improving cognitive function
AU2013344646A1 (en) Methods and compositions for treating schizophrenia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170202